½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1567795

ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå Àü¸Á(-2030³â) : Áö¿ªº° ºÐ¼® - Ä¡·á µî±Þ, Á¦Çü, À¯Çü, ¿©µå¸§ À¯Çü ¹× À¯Åë ä³Îº°

North America Acne Medication Market Forecast to 2030 - Regional Analysis - by Therapeutic Class, Formulation, Type, Acne Type, and Distribution Channel

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 121 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀåÀº 2022³â 33¾ï 6,250¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 47¾ï 9,401¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023³âºÎÅÍ 2030³â±îÁö 4.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯±â³ó/õ¿¬ Ä¡·áÁ¦¿¡ ´ëÇÑ ´ÏÁî Áõ°¡·Î ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå È°¼ºÈ­

±âÁ¸ ½ºÅ²Äɾî Á¦Ç°¿¡ »ç¿ëµÇ´Â ÇÕ¼º ¼ººÐ°ú È­Çй°ÁúÀÇ À¯ÇØÇÑ ¿µÇâ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó, º¸´Ù ¾ÈÀüÇÏ°í ģȯ°æÀûÀΠõ¿¬ ¼ººÐ°ú À¯±â³ó ´ëüǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Àü ¼¼°èÀûÀ¸·Î Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¼ÒºñÀÚµéÀº ÀÚ±ØÀûÀÎ È­Çй°Áú, Àΰø Çâ·á ¹× ÀáÀçÀû ÀÚ±Ø ¹°ÁúÀÌ ¾ø´Â Á¦Ç°À» Á¡Á¡ ´õ ¸¹ÀÌ Ã£°í ÀÖÀ¸¸ç, ½Ä¹° À¯·¡ ¼ººÐ, ½Ä¹° ÃßÃâ¹°, ¿¡¼¾¼È ¿ÀÀÏ ¹× ±âŸ ½ºÅ²Äɾî È¿°ú·Î ¾Ë·ÁÁø õ¿¬ È­ÇÕ¹°ÀÇ ÈûÀ» È°¿ëÇÏ´Â Æ÷¹Ä·¯¸¦ ¼±ÅÃÇÏ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼¿¡ µû¶ó ¸¹Àº ½ºÅ²ÄÉ¾î ºê·£µå¿Í Á¦Á¶¾÷üµéÀÌ °Ç°­À» Áß½ÃÇÏ´Â ¼ÒºñÀÚµéÀÇ ¿ä±¸¿¡ ºÎÀÀÇϱâ À§ÇØ ´Ù¾çÇÑ Ãµ¿¬ ¹× À¯±â³ó ¿©µå¸§ Ä¡·á Á¦Ç°À» °³¹ßÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç°¿¡´Â ƼƮ¸® ¿ÀÀÏ, ¸¶³à °³¾Ï, ¾Ë·Î¿¡ º£¶ó, ³ìÂ÷ ÃßÃâ¹°, »ì¸®½Ç»ê µî õ¿¬ À¯·¡ ¼ººÐÀÌ ÇÔÀ¯µÇ¾î ÀÖ¾î ¿©µå¸§ Ä¡·áÀÇ È¿´ÉÀ» ¼Õ»ó½ÃÅ°Áö ¾ÊÀ¸¸é¼­µµ º¸´Ù ÃÑüÀûÀÌ°í Áö¼Ó °¡´ÉÇÑ ¹æ½ÄÀ¸·Î ¿©µå¸§À» Ä¡·áÇÏ´Â µ¥ µµ¿òÀ» ÁÙ ¼ö ÀÖÀ¸¸ç, À¯±â³ó ½ºÅ²ÄÉ¾î »ç¾÷À» Àü°³ÇÏ´Â ¸¶´Ù¶ó(MADARA)´Â ¹Ì»ý¹° ¹ë·±½Ì ¸ðÀ̽ºÃ³¶óÀÌÀú¿Í °ÇÁ¶ÇÏÁö ¾ÊÀº ¼¼¾ÈÁ¦¶ó´Â µÎ °¡Áö »õ·Î¿î õ¿¬ µ¥Àϸ® ½ºÅ²Äɾî Á¦Ç°À» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ Á¦Ç°µéÀº °úÇаú ÀÚ¿¬À» À¶ÇÕÇÏ¿© °³¹ßµÇ¾úÀ¸¸ç, ¿©µå¸§ÀÌ ¹ß»ýÇϱ⠽¬¿î ´Ù¾çÇÑ ÇǺλöÀ» °¡Áø »ç¶÷µéÀ» ºÎµå·´°Ô ÄɾîÇÒ ¼ö ÀÖµµ·Ï Ưº°ÇÏ°Ô Ã³¹æµÇ¾ú½À´Ï´Ù´Â °ÍÀÌ È¸»ç ÃøÀÇ ¼³¸íÀÔ´Ï´Ù. µÎ Á¦Ç° ¸ðµÎ ºÏºÎ ÁÖ´ÏÆÛ Áٱ⼼Æ÷, ¹ßÈ¿ ´Ù´ç·ù, À̳¢¿Í ¸¶Å×Â÷ ÃßÃâ¹°°ú °°Àº õ¿¬, À¯±â³ó, ºñ°Ç ¼ººÐÀ¸·Î ¸¸µé¾îÁ® ÇǺθ¦ ¼Õ»ó½ÃÅ°Áö ¾Ê°í °áÁ¡À» Àü¹®ÀûÀ¸·Î Ä¡·áÇÕ´Ï´Ù. ¼ºÀΰú û¼Ò³â ¸ðµÎ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌó·³ õ¿¬ ¹× À¯±â³ó ¿©µå¸§ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ÇâÈÄ ¸î ³âµ¿¾È ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀåÀÇ ¹Ì·¡°¡ °è¼Ó Çü¼ºµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

õ¿¬ ¹× À¯±â³ó ¿©µå¸§ Ä¡·á ¿É¼ÇÀ¸·ÎÀÇ ÀüȯÀº ±ÔÁ¦ ´ç±¹ÀÇ ¾ö°ÝÇÑ °¨½Ã¿Í ¾÷°è Ç¥ÁØ°ú °ü·ÃµÈ ÇÕº´Áõ Áõ°¡·Î ÀÎÇØ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹Àº ¼ººÐÀÇ Åõ¸í¼º, ¾ÈÀü¼º, Áö¼Ó°¡´É¼ºÀ» °­Á¶ÇÏ°í ÀÖÀ¸¸ç, ±â¾÷µéÀº ´õ ±ú²ýÇÏ°í ģȯ°æÀûÀÎ ½ºÅ²ÄÉ¾î ¼Ö·ç¼ÇÀ» ¿øÇÏ´Â ¼ÒºñÀÚÀÇ ÃëÇâ¿¡ ¸ÂÃß¾î Á¦Ç°À» °³¼±Çϵµ·Ï Ã˱¸ÇÏ°í ÀÖ½À´Ï´Ù. ÀÌó·³ ½ºÅ²ÄÉ¾î ·çƾ¿¡¼­ õ¿¬ ¼ººÐ°ú ģȯ°æ ¼ººÐÀ» ¿ì¼±½ÃÇÏ´Â ¼ÒºñÀÚµéÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀåÀº ÇâÈÄ ¸î ³âµ¿¾È »õ·Î¿î ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå °³¿ä

ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸ºÐµÇ¸ç, 2022³â ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå Á¡À¯À²Àº ¹Ì±¹ÀÌ °¡Àå ÄǽÀ´Ï´Ù. ¿©µå¸§Àº ¸ð³¶¿¡ ¸ÕÁö, ±â¸§, ÇÇÁö, Á×Àº ÇǺΠ¼¼Æ÷°¡ ¸ð³¶¿¡ ¸·Çô ¹ß»ýÇÏ´Â ÇǺΠÁúȯÀÔ´Ï´Ù. ¹Ì±¹ ÇǺΰú ÇÐȸ¿¡ µû¸£¸é ¿©µå¸§Àº ¹Ì±¹¿¡¼­ °¡Àå ³Î¸® ÆÛÁø Áúº´À¸·Î ¸Å³â 5,000¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ ¿©µå¸§À¸·Î °íÅë¹Þ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ÀÎÀÇ ¿©µå¸§ ¹ß»ý·ü Áõ°¡¿Í ÀÌ¿¡ µû¸¥ ´Ù¾çÇÑ Çõ½ÅÀûÀÎ ¿©µå¸§ Ä¡·áÁ¦ÀÇ Ãâ½Ã·Î ¹Ì±¹ ³» ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀåÀº È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå ¼¼ºÐÈ­

ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀåÀº Ä¡·á Ŭ·¡½º, Á¦Çü, À¯Çü, ¿©µå¸§ À¯Çü, À¯Åë ä³Î ¹× ±¹°¡¸¦ ±âÁØÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù.

Ä¡·áÁ¦ À¯Çü¿¡ µû¶ó ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀåÀº ·¹Æ¼³ëÀ̵å, °ú»êÈ­º¥Á¶ÀÏ, Ç×»ýÁ¦, »ì¸®½Ç»ê, ±âŸ·Î ±¸ºÐµÇ¸ç, 2022³â¿¡´Â ·¹Æ¼³ëÀÌµå ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦Çü Ãø¸é¿¡¼­ ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀåÀº ¿Ü¿ëÁ¦¿Í ³»º¹¾àÀ¸·Î ³ª´¹´Ï´Ù. ¿Ü¿ëÁ¦ ºÎ¹®Àº 2022³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

À¯Çüº°·Î ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀåÀº ó¹æ¾à°ú ÀϹÝÀǾàÇ°À¸·Î ±¸ºÐµÇ¸ç, 2022³â¿¡´Â ó¹æ¾à ºÎ¹®ÀÌ ´õ Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿©µå¸§ À¯Çüº°·Î ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀåÀº ºñ¿°Áõ¼º ¿©µå¸§°ú ¿°Áõ¼º ¿©µå¸§À¸·Î ³ª´µ¸ç, 2022³â¿¡´Â ¿°Áõ¼º ¿©µå¸§ ºÎ¹®ÀÌ ´õ Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯Åë ä³Î Ãø¸é¿¡¼­ ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀåÀº ¾à±¹ ¹× ¾à±¹, ¼Ò¸ÅÁ¡, ÀüÀÚ»ó°Å·¡·Î ±¸ºÐµË´Ï´Ù. ¾à±¹ ¹× ¾à±¹ ºÎ¹®ÀÌ 2022³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ºÐ·ùµÇ¸ç, 2022³â ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀåÀº ¹Ì±¹ÀÌ Áö¹èÀûÀ̾ú½À´Ï´Ù.

Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Almirall SA, Johnson &Johnson, Bausch Health Companies Inc, Centro Internacional de Cosmiatria SA de CV, Galderma SA, Pfizer Inc, GSK Plc, Viatris Inc, Somar Sapi De CV, Italmex SA µîÀÌ ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå¿¡¼­ È°µ¿ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå ±¸µµ

  • PEST ºÐ¼®
  • ¿Ü¿ë¾à°ú °æ±¸¾à °¡°Ý ºÐ¼®
  • ¿©µå¸§ Ä¡·á¸¦ ¹Þ´Â ȯÀÚÃþ

Á¦5Àå ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ÁÖ¿ä ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ÁÖ¿ä ½ÃÀå ±âȸ
  • ÇâÈÄ µ¿Çâ
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ

Á¦6Àå ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå-ºÏ¹Ì ½ÃÀå ºÐ¼®

Á¦7Àå ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® - Ä¡·á Ŭ·¡½ºº°

  • ·¹Æ¼³ëÀ̵å
  • °ú»êÈ­ º¥Á¶ÀÏ
  • Ç×»ýÁ¦
  • »ì¸®½Ç»ê
  • ±âŸ

Á¦8Àå ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® - Á¦Çüº°

  • ¿Ü¿ë¾à
  • °æ±¸¾à

Á¦9Àå ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® - À¯Çüº°

  • ó¹æ¾à
  • ½ÃÆǾà

Á¦10Àå ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® - ¿©µå¸§ À¯Çüº°

  • ºñ¿°Áõ¼º ¿©µå¸§
  • ¿°Áõ¼º ¿©µå¸§

Á¦11Àå ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå ºÐ¼® - À¯Åë ä³Îº°

  • ¾à±¹ ¹× µå·°½ºÅä¾î
  • ¼Ò¸ÅÁ¡
  • E-Commerce

Á¦12Àå ºÏ¹ÌÀÇ ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå : ±¹°¡º° ºÐ¼®

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ

Á¦13Àå ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå-¾÷°è »óȲ

  • ¿©µå¸§ Ä¡·áÁ¦ ½ÃÀå ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«
  • Farmapiel°ú Ÿ»ç ¿©µå¸§ Ä¡·áÁ¦ Á¦Ç° ºñ±³

Á¦14Àå ±â¾÷ °³¿ä

  • Teva Pharmaceutical Industries Ltd
  • Almirall SA
  • Johnson & Johnson
  • Sun Pharmaceutical Industries Ltd
  • Bausch Health Companies Inc
  • Centro Internacional de Cosmiatria SA de CV
  • Galderma SA
  • Pfizer Inc
  • GSK Plc
  • Viatris Inc
  • Somar Sapi De CV
  • Italmex SA

Á¦15Àå ºÎ·Ï

LSH 24.10.31

The North America acne medication market was valued at US$ 3,362.50 million in 2022 and is expected to reach US$ 4,794.01 million by 2030; it is estimated to register at a CAGR of 4.6% from 2023 to 2030.

Upsurge in Need for Organic and Natural Treatments Fuels North America Acne Medication Market

As people are becoming more conscious of the potentially harmful effects of synthetic ingredients and chemicals used in traditional skincare products, the demand for natural and organic alternatives that are deemed to be safer, gentler, and more environmentally friendly is on the rise across the world. Consumers are increasingly seeking products free from harsh chemicals, artificial fragrances, and potentially irritating substances, opting for formulations that harness the power of plant-based ingredients, botanical extracts, essential oils, and other natural compounds known for their skincare benefits. In response to this trend, many skincare brands and manufacturers are developing a wide range of natural and organic acne treatment products that cater to the needs of health-conscious consumers. These products often feature ingredients such as tea tree oil, witch hazel, aloe vera, green tea extract, and salicylic acid derived from natural sources, offering a more holistic and sustainable approach to treating acne without compromising efficacy. In July 2022, MADARA, an organic skincare business, introduced two new and natural everyday skincare products-a microbiome-balancing moisturizer and a non-drying face cleanser. The company claims that these products were developed by blending science and nature, and were specifically formulated to offer gentle treatment for people of different complexions, who are prone to acne. Both products are made with natural, organic, and vegan ingredients-Northern Juniper Stem Cells, fermented polysaccharides, and lichen and Mate tea extracts-which deal specifically with imperfections, keeping the skin unharmed. Adults and teenagers can both utilize this product. Thus, the increasing preference for natural and organic acne treatment options is expected to continue shaping the future of the North America acne medication market in the coming years.

The shift toward natural and organic acne treatment options is also driven by the increasing stringency of regulatory scrutiny and complications associated with industry standards. Regulatory agencies emphasize ingredient transparency, safety, and sustainability, prompting companies to reformulate their products to meet evolving consumer preferences for cleaner and greener skincare solutions. Thus, as more consumers prioritize natural ingredients and eco-friendly formulations in their skincare routines, the North America acne medication market is expected to experience new growth trends in the coming years.

North America Acne Medication Market Overview

The acne medication market in North America is segmented into the US, Canada, and Mexico. The US held the largest North American acne medication market share in 2022. Acne is a skin condition brought on by debris, oil, sebum, and dead skin cells clogging hair follicles. According to the American Academy of Dermatology, acne is the most prevalent illness in the US, up to 50 million Americans suffer from acne each year, making it the most common skin ailment in the country. The acne medication market in this country is projected to expand due to the increased incidence of acne in Americans and the subsequent launch of various innovative acne medications.

North America Acne Medication Market Revenue and Forecast to 2030 (US$ Million)

North America Acne Medication Market Segmentation

The North America acne medication market is segmented based on therapeutic class, formulation, type, acne type, and distribution channel, and country.

Based on therapeutic class, the North America acne medication market is segmented into retinoids, benzoyl peroxide, antibiotics, salicylic acid, and others. The retinoids segment held the largest share in 2022.

In terms of formulation, the North America acne medication market is bifurcated into topical medication and oral medication. The topical medication segment held a larger largest share in 2022.

By type, the North America acne medication market is bifurcated into prescription medicine and over-the-counter medicine. The prescription medicine segment held a larger largest share in 2022.

Based on acne type, the North America acne medication market is bifurcated into non-inflammatory acne and inflammatory acne. The inflammatory acne segment held a larger share in 2022.

In terms of distribution channel, the North America acne medication market is segmented into pharmacies and drug stores, retail stores, and e-commerce. The pharmacies and drug stores segment held the largest share in 2022.

Based on country, the North America acne medication market is categorized into US, Canada, and Mexico. The US dominated the North America acne medication market in 2022.

Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Almirall SA, Johnson & Johnson, Bausch Health Companies Inc, Centro Internacional de Cosmiatria SA de CV, Galderma SA, Pfizer Inc, GSK Plc, Viatris Inc, Somar Sapi De CV, and Italmex SA are some of the leading companies operating in the North America acne medication market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Acne Medication Market Landscape

  • 4.1 PEST Analysis
  • 4.2 Pricing Analysis of Topical and Oral Medication
  • 4.3 Patient Population Undergoing Acne Treatment

5. North America Acne Medication Market - Key Market Dynamics

  • 5.1 Key Market Drivers
    • 5.1.1 Increasing Prevalence of Severe Acne
    • 5.1.2 Launch of Novel Drugs
  • 5.2 Key Market Restraints
    • 5.2.1 Side Effects Associated with Acne Medication
  • 5.3 Key Market Opportunities
    • 5.3.1 Individualized Treatment Programs Based on Cutting-Edge Technologies and Data-Driven Strategies
  • 5.4 Future Trends
    • 5.4.1 Upsurge in Need for Organic and Natural Treatments
  • 5.5 Impact of Drivers and Restraints:

6. Acne Medication Market - North America Market Analysis

7. North America Acne Medication Market Analysis - by Therapeutic Class

  • 7.1 Retinoids
    • 7.1.1 Overview
    • 7.1.2 Retinoids: North America Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Benzoyl Peroxide
    • 7.2.1 Overview
    • 7.2.2 Benzoyl Peroxide: North America Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Antibiotics
    • 7.3.1 Overview
    • 7.3.2 Antibiotics: North America Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Salicylic Acid
    • 7.4.1 Overview
    • 7.4.2 Salicylic Acid: North America Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Others
    • 7.5.1 Overview
    • 7.5.2 Others: North America Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Acne Medication Market Analysis - by Formulation

  • 8.1 Topical Medication
    • 8.1.1 Overview
    • 8.1.2 Topical Medication: North America Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.2 Oral Medication
    • 8.2.1 Overview
    • 8.2.2 Oral Medication: North America Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Acne Medication Market Analysis - by Type

  • 9.1 Prescription Medicine
    • 9.1.1 Overview
    • 9.1.2 Prescription Medicine: North America Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.2 Over-the-Counter Medicine
    • 9.2.1 Overview
    • 9.2.2 Over-the-Counter Medicine: North America Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Acne Medication Market Analysis - by Acne Type

  • 10.1 Non-Inflammatory Acne
    • 10.1.1 Overview
    • 10.1.2 Non-Inflammatory Acne: North America Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.2 Inflammatory Acne
    • 10.2.1 Overview
    • 10.2.2 Inflammatory Acne: North America Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)

11. North America Acne Medication Market Analysis - by Distribution Channel

  • 11.1 Pharmacies and Drug Stores
    • 11.1.1 Overview
    • 11.1.2 Pharmacies and Drug Stores: North America Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.2 Retail Stores
    • 11.2.1 Overview
    • 11.2.2 Retail Stores: North America Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.3 E-Commerce
    • 11.3.1 Overview
    • 11.3.2 E-Commerce: North America Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)

12. North America Acne Medication Market - Country Analysis

  • 12.1 North America
    • 12.1.1 North America: Acne Medication Market - Revenue and Forecast Analysis - by Country
      • 12.1.1.1 North America: Acne Medication Market - Revenue and Forecast Analysis - by Country
      • 12.1.1.2 US
      • 12.1.1.3 US: Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.3.1 US: Acne Medication Market Breakdown, by Therapeutic Class
        • 12.1.1.3.2 US: Acne Medication Market Breakdown, by Formulation
        • 12.1.1.3.3 US: Acne Medication Market Breakdown, by Type
        • 12.1.1.3.4 US: Acne Medication Market Breakdown, by Acne Type
        • 12.1.1.3.5 US: Acne Medication Market Breakdown, by Distribution Channel
      • 12.1.1.4 Canada
      • 12.1.1.5 Canada: Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.5.1 Canada: Acne Medication Market Breakdown, by Therapeutic Class
        • 12.1.1.5.2 Canada: Acne Medication Market Breakdown, by Formulation
        • 12.1.1.5.3 Canada: Acne Medication Market Breakdown, by Type
        • 12.1.1.5.4 Canada: Acne Medication Market Breakdown, by Acne Type
        • 12.1.1.5.5 Canada: Acne Medication Market Breakdown, by Distribution Channel
      • 12.1.1.6 Mexico
      • 12.1.1.7 Mexico: Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.7.1 Mexico: Acne Medication Market Breakdown, by Therapeutic Class
        • 12.1.1.7.2 Mexico: Acne Medication Market Breakdown, by Formulation
        • 12.1.1.7.3 Mexico: Acne Medication Market Breakdown, by Type
        • 12.1.1.7.4 Mexico: Acne Medication Market Breakdown, by Acne Type
        • 12.1.1.7.5 Mexico: Acne Medication Market Breakdown, by Distribution Channel

13. Acne Medication Market- Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in Acne Medication Market
  • 13.3 Organic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Inorganic Growth Strategies
    • 13.4.1 Overview
  • 13.5 Product Offered by Farmapiel vs Other Companies Acne Products

14. Company Profiles

  • 14.1 Teva Pharmaceutical Industries Ltd
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Almirall SA
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Johnson & Johnson
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 Sun Pharmaceutical Industries Ltd
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 Bausch Health Companies Inc
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 Centro Internacional de Cosmiatria SA de CV
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 Galderma SA
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 Pfizer Inc
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 GSK Plc
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 Viatris Inc
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments
  • 14.11 Somar Sapi De CV
    • 14.11.1 Key Facts
    • 14.11.2 Business Description
    • 14.11.3 Products and Services
    • 14.11.4 Financial Overview
    • 14.11.5 SWOT Analysis
    • 14.11.6 Key Developments
  • 14.12 Italmex SA
    • 14.12.1 Key Facts
    • 14.12.2 Business Description
    • 14.12.3 Products and Services
    • 14.12.4 Financial Overview
    • 14.12.5 SWOT Analysis
    • 14.12.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners
  • 15.2 Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦